Last reviewed · How we verify
Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study
Comorbid substance abuse leads to many deleterious effects such as medical comorbidities and nonadherence, which is one of the most problematic issues. People with schizophrenia and substance use disorders (SUDs) are at an increased risk nonadherence compared to those who do not use alcohol and illicit drugs. The investigators propose that this new marketed injectable antipsychotic with many benefits over other available long acting injectable agents would be beneficial in the dually diagnosed population and may represent a specific schizophrenia subpopulation where long acting agents may be considered an important therapeutic option.
Details
| Lead sponsor | University of Maryland, Baltimore |
|---|---|
| Phase | NA |
| Status | WITHDRAWN |
| Start date | 2014-01 |
| Completion | 2014-01 |
Conditions
- Schizophrenia
Interventions
- Paliperidone
Primary outcomes
- Long acting paliperidone palmitate will improve psychotic, negative and depressive symptoms from baseline to endpoint — 7 months
Long acting paliperidone palmitate will improve psychotic, negative and depressive symptoms from baseline to endpoint during six months of treatment. Improvement in psychotic symptoms will be measured by decrease in the Brief Psychiatric Rating Scale (BPRS) psychosis score. Improvement in negative symptoms will be measured by decrease in the Scale for the Assessment of Negative Symptoms (SANS) total score. Improvement in depressive symptoms will be measured by decrease in Calgary Depression Scale (CDS) total score.
Countries
United States